This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Company type | Public |
---|---|
| |
Industry | Biotechnology |
Founded | 1981 |
Headquarters | Sydney, Australia |
Key people | Dig Howitt (CEO) Ms Alison Deans (Chair) |
Products | Cochlear implants Bone-anchored hearing aids Cochlear wireless accessories Bone anchored prosthetics |
Revenue | A$1,240 million (2017) [1] |
A$224 million (2017) [1] | |
Number of employees | 4,800 in 50 countries (2023)[2] |
Website | www.cochlear.com |
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.[3]
Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate.[4][5] As of 2022, the company holds 50% of the cochlear implant market,[6] with more than 250,000 people receiving one of Cochlear's implants as of 2015.[3]
Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003,[7] and one of the world's most innovative companies by Forbes in 2011.[8]